search
Back to results

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Primary Purpose

Asthma, House Dust Mite Allergy

Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
SLIT tablets of house dust mite allergen extracts
Matching placebo
Sponsored by
Stallergenes Greer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent.
  • Male or female patient from 18 to 50 years.
  • Diagnosed asthma with medical history consistent with HDM-induced allergic asthma.
  • Positive SPT to House Dust Mites(HDM)and HDM-specific IgE serum value ≥ 0.7 kU/L.
  • Stable asthma treatments.
  • Spirometry with best FEV1 > 70% of the predicted value.
  • Spirometry with reversibility of FEV1 of ≥ 12% and ≥ 200 mL.
  • Asthma Control Test™ (ACT) score ≥ 20.

Exclusion Criteria:

  • Current smoker or former smoker with > 10 pack/year history.
  • Co-sensitisation to any allergen possibly leading to clinically relevant respiratory allergy likely to significantly change the symptoms of the patient throughout the treatment period.
  • Patient with a past or current disease, which as judged by the Investigator, may affect the patient's participation in or the outcome of this study.
  • Patient with any oral condition that could confound the safety assessments or planning to have a dental extraction during the study.
  • Female patient pregnant or breast-feeding/lactating.
  • Female patient of childbearing potential not using a medically accepted contraceptive method.
  • Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs).
  • Patient who received allergen immunotherapy for HDM in the last 10 years.
  • Ongoing treatment by immunotherapy with another allergen.

Sites / Locations

  • CHU Arnaud de Villeneuve

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

SLIT tablets of HDM allergen extracts

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Safety, tolerability as indicated by adverse events and safety laboratory evaluation

Secondary Outcome Measures

Full Information

First Posted
May 25, 2012
Last Updated
June 30, 2014
Sponsor
Stallergenes Greer
search

1. Study Identification

Unique Protocol Identification Number
NCT01608243
Brief Title
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
Official Title
Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stallergenes Greer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, House Dust Mite Allergy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
94 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SLIT tablets of HDM allergen extracts
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
SLIT tablets of house dust mite allergen extracts
Intervention Description
10 dosing days
Intervention Type
Biological
Intervention Name(s)
Matching placebo
Intervention Description
10 dosing days
Primary Outcome Measure Information:
Title
Safety, tolerability as indicated by adverse events and safety laboratory evaluation
Time Frame
10 dosing days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent. Male or female patient from 18 to 50 years. Diagnosed asthma with medical history consistent with HDM-induced allergic asthma. Positive SPT to House Dust Mites(HDM)and HDM-specific IgE serum value ≥ 0.7 kU/L. Stable asthma treatments. Spirometry with best FEV1 > 70% of the predicted value. Spirometry with reversibility of FEV1 of ≥ 12% and ≥ 200 mL. Asthma Control Test™ (ACT) score ≥ 20. Exclusion Criteria: Current smoker or former smoker with > 10 pack/year history. Co-sensitisation to any allergen possibly leading to clinically relevant respiratory allergy likely to significantly change the symptoms of the patient throughout the treatment period. Patient with a past or current disease, which as judged by the Investigator, may affect the patient's participation in or the outcome of this study. Patient with any oral condition that could confound the safety assessments or planning to have a dental extraction during the study. Female patient pregnant or breast-feeding/lactating. Female patient of childbearing potential not using a medically accepted contraceptive method. Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase inhibitors (MAOIs). Patient who received allergen immunotherapy for HDM in the last 10 years. Ongoing treatment by immunotherapy with another allergen.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pascal Demoly, MD
Organizational Affiliation
CHU Arnaud de Villeneuve, Montpellier, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Arnaud de Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Learn more about this trial

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

We'll reach out to this number within 24 hrs